Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;18(1-2):169-182.
doi: 10.1007/s11481-023-10066-x. Epub 2023 May 11.

Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV

Mattia Trunfio  1   2 , Lorenzo Mighetto  3 , Laura Napoli  4 , Cristiana Atzori  5 , Marco Nigra  3 , Giulia Guastamacchia  5 , Stefano Bonora  4 , Giovanni Di Perri  4 , Andrea Calcagno  4
Affiliations

Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV

Mattia Trunfio et al. J Neuroimmune Pharmacol. 2023 Jun.

Abstract

Plasma C-X-C-motif chemokine ligand-13 (CXCL13) has been linked to disease progression and mortality in people living with HIV (PLWH) and is a candidate target for immune-based strategies for HIV cure. Its role in central nervous system (CNS) of PLWH has not been detailed. We described CSF CXCL13 levels and its potential associations with neurological outcomes. Cross-sectional study enrolling PLWH without confounding for CXCL13 production. Subjects were divided according to CSF HIV-RNA in undetectable (< 20 cp/mL) and viremics. CSF CXCL13, and biomarkers of blood-brain barrier (BBB) impairment, intrathecal synthesis, and immune activation were measured by commercial immunoturbidimetric and ELISA assays. All subjects underwent neurocognitive assessment. Sensitivity analyses were conducted in subjects with intact BBB only. 175 participants were included. Detectable CSF CXCL13 was more common in the viremic (31.4%) compared to the undetectable group (13.5%; OR 2.9 [1.4-6.3], p = 0.006), but median levels did not change (15.8 [8.2-91.0] vs 10.0 [8.1-14.2] pg/mL). In viremics (n = 86), CXCL13 associated with higher CSF HIV-RNA, proteins, neopterin, intrathecal synthesis and BBB permeability. In undetectable participants (n = 89), CXCL13 associated with higher CD4+T-cells count, CD4/CD8 ratio, CSF proteins, neopterin, and intrathecal synthesis. The presence of CXCL13 in the CSF of undetectable participants was associated with increased odds of HIV-associated neurocognitive disorders (58.3% vs 28.6%, p = 0.041). Sensitivity analyses confirmed all these findings. CXCL13 is detectable in the CSF of PLWH that show increased intrathecal IgG synthesis and immune activation. In PLWH with CSF viral suppression, CXCL13 was also associated with neurocognitive impairment.

Keywords: Blood-brain barrier; CXCL13; HIV; HIV-associated neurocognitive disorders; Humoral response; Intrathecal synthesis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Alvarez E, Piccio L, Mikesell RJ et al (2013) CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler 19:1204–1208. https://doi.org/10.1177/1352458512473362 - DOI - PubMed - PMC
    1. Antinori A, Arendt G, Becker JT et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799. https://doi.org/10.1212/01.WNL.0000287431.88658.8b - DOI - PubMed
    1. Avettand-Fènoël V, Hocqueloux L, Ghosn J et al (2016) Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications. Clin Microbiol Rev 29:859–880. https://doi.org/10.1128/CMR.00015-16 - DOI - PubMed - PMC
    1. Barco A, Orlando S, Stroffolini G et al (2022) Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders. J Neurovirol. https://doi.org/10.1007/s13365-021-01047-y - DOI - PubMed
    1. Beck SE, Queen SE, Viscidi R et al (2016) Central nervous system-specific consequences of simian immunodeficiency virus gag escape from major histocompatibility complex class I-mediated control. J Neurovirol 22:498–507. https://doi.org/10.1007/s13365-015-0420-5 - DOI - PubMed - PMC

Publication types

LinkOut - more resources